AliveGen USA Inc.
http://www.alivegen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AliveGen USA Inc.
Biogen Acquires Ionis’ Spinal Muscular Atrophy Candidate As Spinraza Loses Its Shine
The firm has stumped up $60m for Ionis’s preclinical antisense asset in spinal muscular atrophy, a potential successor to the slowing Spinraza, which also faces patent expiry in a few years.
Newly Approved OTC Eye Drop Could Boost Valeant Turnaround Outlook
Valeant's Bausch + Lomb subsidiary will have market exclusivity for Lumify, the first OTC brimonidine eye drop. It likely will provide a needed revenue boost as the parent firm navigates a turnaround after incurring more than $30bn debt during the turbulent period under previous management.
Newly Approved OTC Eye Drop Could Boost Valeant Turnaround Outlook
Valeant's Bausch + Lomb subsidiary will have market exclusivity for Lumify, the first OTC brimonidine eye drop. It likely will provide a needed revenue boost as the parent firm navigates a turnaround after incurring more than $30bn debt during the turbulent period under previous management.
Execs On The Move, June 2016
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice